-
Broncus Medical’s BroncQCT Approved by Zhejiang Administration for China Market Entry
•
Broncus Medical Inc., a provider of precision intervention solutions for lung diseases with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), has received approval from the Zhejiang Medical Products Administration to market its BroncQCT lung image processing software in China. Software FunctionalityBroncQCT processes CT images through advanced…
-
Broncus Medical Inc. Reports 32% YOY Growth in 2023, Highlighted by Strength in China
•
Broncus Medical Inc. (HKG: 2216), a provider of precision intervention solutions for lung diseases with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has released its financial report for 2023. The company reported product sales of USD 12.41 million for the period, marking a robust…
-
Broncus Medical and Hangzhou Norchant Terminate Licensing Agreement with Cancellation Fee
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai and Hangzhou, China, and San Jose and Seattle, United States, has announced the termination of a licensing agreement between its subsidiary Broncus Medical and Hangzhou Norchant, which was originally signed in September 2021.…
-
Broncus Medical Inc. to Acquire Fibernova Holding Corporation for USD 2.7 Million
•
Broncus Medical Inc., (HKG: 2216) a provider of lung disease precision intervention solutions with operations in Shanghai, Hangzhou (China), and San Jose, Seattle (United States), is set to fully acquire Fibernova Holding Corporation for a total consideration of USD 2.7 million. The acquisition includes a USD 1.7 million equity exchange…
-
Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System
•
China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung diseases, has announced the start of its first regulatory clinical study for its targeted lung denervation (TLD) radiofrequency ablation system. This multi-center, randomized study will be conducted across 26 centers, aiming to assess the safety…
-
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
•
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based in China, has joined forces with Venus Medtech (Hangzhou) Inc., another prominent player in the medical field (HKG: 2500), to announce the establishment of a partnership fund. Each company is contributing RMB 125 million (USD…
